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Abstract
Purpose Guidelines advocate remote monitoring (RM) in pa-
tients with a cardiac implantable electronic device (CIED).
However, it is not known when RM should be initiated. We
hypothesized that prompt initiation of RM (within 91 days of
implant) is associated with improved survival compared to
delayed initiation.
Methods This retrospective, national, observational cohort
study evaluated patients receiving new implants of market-
released St. Jude Medical™ pacemakers (PM), implantable
ca rd iove r t e r de f i b r i l l a t o r s ( ICD) , and ca rd i a c
resynchronization therapy (CRT) devices. Patients were
assigned to one of two groups: an BRM Prompt^ group, in
which RM was initiated within 91 days of implant; and an
BRM Delayed^ group, in which RM was initiated >91 days
but ≤365 days of implant. The primary endpoint was all-cause
mortality.
Results The cohort included 106,027 patients followed
for a mean of 2.6 ± 0.9 years. Overall, 47,014 (44 %)
patients had a PM, 31,889 (30 %) patients had an ICD,
24,005 (23 %) patients had a CRT-D, and 3119 (3 %)
patients had a CRT-P. Remote monitoring was initiated
promptly (median 4 weeks [IQR 2, 8 weeks]) in 66,070
(62 %) patients; in the other 39,957 (38 %) patients,
RM initiation was delayed (median 24 weeks [IQR 18,
34 weeks]). In comparison to delayed initiation, prompt
initiation of RM was associated with a lower mortality
rate (4023 vs. 4679 per 100,000 patient-years, p< 0.001)
and greater adjusted survival (HR 1.18 [95 % CI 1.13–
1.22], p< 0.001).
Conclusions Our data, for the first time, show improved sur-
vival in patients enrolled promptly into RM following CIED
implantation. This advantage was observed across all CIED
device types.
Keywords Cardiac implantable electronic device . Remote
monitoring . Survival . Time to enrollment
1 Introduction
Hundreds of thousands of cardiac implantable electronic
devices (CIEDs) are implanted worldwide annually [1, 2].
As indications have expanded and technology has
improved, the incidence of device implantation has
increased. Guidelines have been developed to guide the
frequency and method of follow-up for CIED patients
[1, 3]. It is accepted that all patients should be seen
in-person within 2–12 weeks of device implantation.
Subsequently, patients have typically been seen quarterly
for in-person evaluation.
The technology now exists for physicians to remotely
access data from their patients’ CIEDs, including diagnos-
tic data (arrhythmia burden, transthoracic impedance) and
lead parameters (pacing impedance, capture threshold). In
fact, it has been shown that CIED patients who are mon-
itored remotely have improved survival [4–6]. While the
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majority of prior work has focused on patients implanted
with an ICD or CRT-D, the survival benefit is maintained
across all CIED types (including pacemakers) and is en-
hanced by high adherence to RM [7]. Thus, current guide-
lines advocate remote monitoring (RM) over calendar-
based in-person only device follow-up [3].
However, an unresolved issue is the timing of RM enroll-
ment and activation relative to device implantation itself.
Several device manufacturers now offer BPoint of Care^
(POC) pairing, in which a patient’s newly implanted CIED is
synchronized with their remote transmitter prior to hospital
discharge or at the first in-office visit. In a small pilot study
of radiofrequency-enabled pacemaker patients, POC pairing
was associated with increased RM compliance at 2 months
post-implant [8]. Whether prompt initiation of RM translates
into improved clinical outcomes is unknown.We hypothesized
that prompt initiation of RM, defined as within 91 days of
CIED implantation, is associated with improved survival com-
pared to delayed initiation. The aim of this study was to assess
this hypothesis in a large national cohort of CIED patients.
2 Methods
Study design and patient selection This retrospective, na-
tional, observational cohort study evaluated patients receiving
new implants of a market-released St. Jude Medical™
radiofrequency-enabled pacemaker (PM), implantable
cardioverter defibrillator (ICD), cardiac resynchronization
therapy (CRT)-pacemaker (CRT-P), or CRT-defibrillator
(CRT-D). To assess the impact of RM initiation on outcome,
patients whose implanted device did not support automatic
(Bwandless^) daily monitoring were excluded (not automatic
RM capable, Fig. 1). Among Bautomatic RM capable^ pa-
tients who were active on RM, an index event (RM0) was
defined as the time of first connection between a patient’s
Merlin@home monitor and the central server. Only
Bautomatic RM active^ patients in whom RM0 occurred with-
in 1 year of implant were included in the study. The remaining
patients with an ICD or CRT-D device implanted between
October 2008 and November 2011 and a PM or CRT-P device
implanted between October 2009 and November 2011 com-
prised the study cohort. Among these, patients enrolled in
another clinical trial, or with follow-up time <90 days, were
excluded. Included patients were followed until death, device
replacement, or device removal through November 2013.
Data acquisition Study data were obtained from four sources:
device implant registration from St. Jude Medical, Inc.
(Sylmar, CA), Merlin.net™ remote monitoring system, the
2012 American Community Survey (ACS) of the US
Census, and the US Social Security Death Index (SSDI)
Master File. Age at implant, gender, patient ZIP code, device
model number, date of implant, and follow-up duration were
ascertained using manufacturer device tracking data. De-
identified data from weekly Merlin.net™ maintenance trans-
missions were linked to implant registration data to determine
RM status. The date of death was determined from the SSDI, a
database of internal records from the US Social Security
Administration Death Master File, with all death records
through November 30, 2013. The SSDI contains records of
>94 million deceased individuals in the US and maintains
high accuracy in determination of mortality status, with in-
creased sensitivity in patients >65 years [9–11]. We added
death reports made directly to the device manufacturer’s US
tracking system by healthcare providers or family members
(accounting for <1 % of deaths) through November 30, 2013.
Socioeconomic data was gathered from the 2012 ACS by
individual ZIP code tabulation area (ZCTA). The ACS
ZCTA-based data was then linked to individual patient ZIP
codes for the following data in percent of population in ZCTA,
except as noted: 4-year college degree, median income, below
poverty level, Supplemental Nutrition Assistance Program
(SNAP) recipient, telephone or cell phone service, employ-
ment status, labor force participation rate (LFPR), civilian
population proportion, healthcare insurance, racial population
proportions (White, Black, American Indian, Asian, two
races, other), and total urban/rural classification of population
counts. The urban percentage for a region was computed as
the ratio of urban to total population counts.
Determination of time to remote monitoring Among auto-
matic RM active patients, the time to RM was defined as the
number of days between implant and RM0. To determine
whether the timing of RM initiation affects outcome, automat-
ic RM active patients were assigned to one of two groups
based on the computed time to RM. Patients with time to
RM≤91 days comprised the BRM Prompt^ group, and those
with 91 days< time to RM≤365 days constituted the BRM
Delayed^ group. A pre-determined cutoff of 91 days was se-
lected based on the 2008HRS/EHRA expert consensus guide-
line that all CIED patients be seen in person within 12 weeks
of device implant [1].
Statistical analysis The primary endpoint for this study was
all-cause mortality. Mortality was determined using unadjust-
ed mortality incidence rates and adjusted survival via Cox
proportional hazards survival models. The mortality incidence
rate ratio (RM Delayed/RM Prompt) and 95 % confidence
intervals (CI) were determined from the patient deaths and
the computed follow-up duration within each group. All-
cause survival was compared among patients within the RM
Prompt and RMDelayed groups using multivariable Cox pro-
portional hazards modeling with stratification on age and co-
variates of gender, device type (for groupings with >1 device
type), and the RM predictor census variables. Covariates were
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evaluated between the RM Prompt and RM Delayed groups
using logistic regression and stepwise backward elimination
for p values ≤ 0.2. These variables were then used for adjust-
ment in the survival regression to determine the Cox propor-
tional hazard ratio (HR) and 95% CI. Follow-up duration was
calculated for each patient as the time from device implant
until device explant, device replacement, death, or end of
study surveillance.
All statistical analyses were performed with Revolution R
Open 3.2.1. Patient demographics were assessed as mean and
standard deviation, median and quartiles, or count and propor-
tion. The p value for means comparison was Student’s t test
and for counts was Chi square.
3 Results
The study cohort included 106,027 patients. The mean
age of the patients was 71 ± 13 years, and 68,159 (64 %)
patients were male. Overall, 47,014 (44 %) patients had a
PM, 31,889 (30 %) patients had an ICD, 24,005 (23 %)
patients had a CRT-D, and 3119 (3 %) patients had a
CRT-P device. Patients were followed for a mean of 2.6
± 0.9 years. By design, all patients were enrolled in
automatic (wandless) RM. The median time to RM for
the entire cohort was 8 weeks (IQR 4, 20 weeks).
Fig. 1 Flowchart of patients
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Table 1 Comparison of patients based on time to enrollment into
remote monitoring following CIED device implantation
RM0 ≤ 91 days,
n= 66,070
RM0 > 91 days,
n= 39,957
Age, years 72 ± 13 71± 13
Sex, male 42,207 (64 %) 25,952 (65 %)
Device type
CRT-pacemaker 2030 (3 %) 1089 (3 %)
CRT-defibrillator 13,971 (21 %) 10,034 (25 %)
ICD 18,300 (28 %) 13,589 (34 %)
Pacemaker 31,769 (48 %) 15,245 (38 %)
Follow-up, years 2.7 ± 0.9 2.5 ± 1.0
Time to first RM, weeks
[IQR]
4 (2, 8) 24 (18, 34)
Due to the large sample size, comparison between groups yields differ-
ences that are very small in magnitude and not clinically meaningful but
statistically significant. Thus, the p values are not shown
CRT cardiac resynchronization therapy, ICD implantable cardioverter-de-
fibrillator, IQR interquartile range, RM remote monitoring, RM0 number
of days between CIED implant and RM initiation
Remote monitoring was initiated within 91 days of implant
in 66,070 (62 %) patients (Table 1). In these patients, RMwas
initiated at a median of 4 weeks (IQR 2, 8 weeks) following
device implantation. There were 39,957 (38 %) patients in
whom RM was initiated after 91 days of device implantation
(but still within the first year). In these patients, RM was
initiated at a median of 24 weeks (IQR 18, 34 weeks). For
the overall cohort, the number of weeks between implant and
RM0 is illustrated in the Fig. 2. This distribution was similar
across all CIED device types; however, there were numerical-
ly a higher proportion of patients with delayed RM initiation
in the ICD and CRT-D cohorts (43 and 42 %, respectively)
compared to the PM and CRT-P cohorts (32 and 35%, respec-
tively). Patients (matched to individual ZIP codes) in both
groups were similar with respect to all socio-demographic
characteristics assessed in this study (Table 2).
In comparison to patients with delayed initiation of RM,
patients in whom RMwas initiated promptly had a lower mor-
tality incidence rate (4023 vs. 4679 per 100,000 patient-years,
p<0.001) (Table 3). This relationship held across all CIED
types. Unadjusted mortality incidence rates were highest in
the CRT population. The adjusted survival was significantly
greater in patients in whomRMwas started promptly (HR 1.18
[95 % CI 1.13–1.22], p<0.001, Fig. 2). The magnitude of this
Fig. 2 Timing of remote
monitoring initiation and its
impact on patient survival. In this
study, remote monitoring was
promptly initiated (≤91 days post-
implant) in 66,070 (62 %)
patients; in the other 39,957
(38 %) patients, RM initiation
was delayed (>91 days) within the
first year post-implant (top). Early
activation of remote monitoring
was associated with improved
patient survival for all devices
(bottom)
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relationship was similar across each device type, but was
greatest for patients implanted with CRT-D devices (HR 1.20
[95 % CI 1.13–1.28], p<0.001, Fig. 3).
4 Discussion
Prior prospective and observational mega-cohort studies
have demonstrated an association between remote moni-
toring of CIED patients and improved survival [4–7]. Our
data, for the first time, show the importance of prompt
enrollment into remote monitoring following CIED
implantation. Patients with RM activation within 3 months
of CIED implantation had an 18 % increased survival
during a mean follow-up of 2.6 years. This advantage
was observed across all CIED device types, highlighting
the consistency and relevance of these findings for all
patients with cardiac rhythm devices.
In the current study, CRT-D patients exhibited the larg-
est survival benefit with prompt initiation of RM. While
the precise mechanism for this effect is not yet fully un-
derstood, our results align with findings from the IN-
TIME trial. This randomized trial showed ICD and CRT-
D patients with heart failure in whom RM was utilized in
the year post-device implant had a significantly lower
likelihood of the composite endpoint of all-cause death,
overnight hospital admission for heart failure, change in
NYHA class, and change in patient global self-assessment
[6]. Three mechanisms were proposed for the observed
benefit: (1) early detection of ventricular and atrial tachy-
arrhythmias, (2) early recognition of suboptimal device
function such as low percent biventricular pacing and in-
appropriate shocks, and (3) patient interview prompted by
remote monitoring, which occasionally revealed symp-
tomatic worsening or noncompliance to drugs. Since pa-
tients most vulnerable to repeated heart failure hospitali-
zations have the highest mortality, prompt correction of
potentially destabilizing conditions (enabled by RM) is
likely to improve future survival [12].
Importantly, the association between prompt initiation
of RM and improved survival was observed across all
CIED types. In ICD patients, RM has been associated
with a lower likelihood of inappropriate and appropriate
shocks [13], reduced time from event to clinical deci-
sion [14], and earlier detection of arrhythmias and hard-
ware malfunction, initiating both surgical and noninva-
sive (reprogramming, introduction of antiarrhythmics)
interventions [15, 16]. This effect was maintained even
when the analysis was limited to the first 3 months
post-implant, suggesting that early RM promotes the
detection of actionable events immediately following
ICD implant [17]. In PM patients, early detection of
atrial arrhythmias via RM may result in alteration of
Table 3 Mortality rate table
Mortality incidence rate per 100,000 patient-years Mortality incidence
rate ratioa
p value
RM0 ≤ 91 days RM0 > 91 days
All devices 4,023 4,679 1.2 <0.001
CRT-defibrillator 5,539 6,473 1.2 <0.001
CRT-pacemaker 5,135 5,898 1.2 <0.001
ICD 3,668 4,002 1.1 <0.001
Pacemaker 3,480 4,010 1.2 <0.001
aMIRR=MIRDelayed/MIRPrompt
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Table 2 Socio-demographic data




Bachelor’s degree 26 (15) 26 (15)
Median income 54 (21) 55 (22)
Below poverty line 14 (8) 13 (8)
Have telephone 98 (2) 98 (2)
Receive SNAP 1 (1) 1 (1)
Uninsured 14 (7) 14 (7)
Residence: urban 71 (36) 73 (35)
Not in labor force
(1-LPFR)
37 (9) 37 (9)
Unemployed 9 (4) 9 (4)
Civilian 62 (9) 62 (8)
Race: White 80 (19) 79 (20)
Race: Black 11 (17) 12 (18)
Race: Indian
(American)
1 (3) 1 (3)
Race: Asian 3 (6) 3 (06)
Race: two races 2 (2) 2 (2)
Race: other 3 (5) 3 (5)
a Values reported as mean (standard deviation). All parameters in this
section were measured as percent in ZIP code except median income,
which was thousands of dollars in ZIP code. There are 16,385 unique
ZIPs in the BRM Early^ group and 13,683 in the BRM Delayed^ group.
Due to the large sample size, comparison between groups yields differ-
ences that are very small in magnitude and not clinically meaningful but
statistically significant. Thus, the p values are not shown
management that translates to fewer strokes and associ-
ated hospitalizations [18].
Despite these data and guideline recommendations to
incorporate RM in the care of all CIED patients, many
challenges remain, and between a third and half of all
patients with an implanted CIED never activate RM [19].
Identifying the barriers to early RM initiation is para-
mount to developing clinical solutions and improving
outcomes for CIED patients. The PREDICT-RM study
found that RM enrollment is dictated primarily by the
local practice at the institution at which the CIED is
implanted [20]. Additional patient-related variables that
influenced RM activation included race, ethnicity, health
insurance status, geographic location, age, procedure-
related indications and adverse events, and the presence
of co-morbidities such as lung disease, renal dysfunction,
hyponatremia, and atrial arrhythmias [20]. PREDICT-RM
did not, however, investigate the timing of RM initiation,
and it is unknown whether similar factors mediate
prompt vs. delayed RM activation.
It has been postulated that initiation of RM may be more
likely in patients who are generally more compliant with rec-
ommended therapy, such as diet, medications, and/or contact
with their physicians. However, it is also possible that RM
actually induces a Bhealthy user effect.^ In particular, CIED
patients who are remotely monitored are less likely to be lost
to follow-up and more likely to adhere to in-person follow-up
[21]. This effect may be amplified over time in patients who
commit promptly to RM, although the absence of patient and
physician characteristics in the current dataset does not allow
for investigation into this hypothesis.
Data from prior randomized trials, observational stud-
ies, and meta-analyses indicate that routine use of RM in
CIED patients is associated with a reduction in healthcare
Fig. 3 Survival in patients who did or did not promptly enroll in remote monitoring after device implantation, stratified by type of cardiac implantable
electronic device
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utilization costs [14, 22–25]; however, none of these stud-
ies have investigated the impact of early RM initiation on
healthcare costs. Given the improved clinical outcomes
associated with prompt post-implant RM activation, one
may speculate there could be an associated economic ben-
efit, but further investigation is required to draw this
connection.
Our data included only patients who initiated wireless
RM within 1 year of CIED implant, with the intent of
mitigating potential biases associated with unusual follow-
up patterns. The increased survival associated with prompt
initiation of RM, irrespective of CIED type, suggests that
we may have an opportunity to improve outcomes by sim-
ply changing our post-CIED implant workflow. Our data
support current consensus guidelines, which suggest enroll-
ing patients into RM within 2 weeks of device implantation
[3]. The guidelines further note that by activating RM prior
to hospital discharge, also known as BPoint of Care^
pairing, a clinic may confirm successful transmission or
troubleshoot technical/compliance issues at the first in-
office device check [3]. This strategy has been previously
associated with increased RM compliance in pacemaker
patients [8]. We show, for the first time, that prompt initi-
ation of RM is associated with improved survival across all
CIED device types.
Limitations There are several limitations to this retrospec-
tive, observational study. First, it is not possible to deter-
mine why some patients promptly engaged with RM post-
CIED implant whereas others delayed initiation.
Additionally, it is not possible to know whether delay
was related to failure to enroll patients promptly into
RM or failure of an enrolled patient to activate their re-
mote monitor. We also do not have information regarding
the timing or frequency of in-clinic device follow-up dur-
ing this first year. Finally, it is not possible to ascertain
the mechanism of the survival benefit observed in the
patients enrolled early into RM. We do not have informa-
tion about device or arrhythmia-related issues that may
have been detected early post-device implant in the pa-
tients who were promptly enrolled into RM. Recognition
and intervention to correct these issues may have contrib-
uted to the observed survival benefit in our cohort.
Similarly, while we did adjust for patient age and gender,
minimal clinical characteristics are available for our co-
hort, and the potential for patient or physician bias cannot
be excluded.
Conclusions Following CIED implantation, all patients
should be offered enrollment into RM. Patients should be
educated on the association between RM and improved
outcomes (including survival) and be reminded that the
benefit appears to begin early post-CIED implantation.
Subsequent efforts can then be directed to ensure a high
adherence to RM over time, which is necessary to derive
the maximal benefit with this technology.
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